Alzheimer’s Disease (AD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 Alzheimer's disease (AD) is the foremost cause of dementia, accounting for approximately 60% to 80% of all cases of dementia. This condition is a progressive and neurodegenerative ailment characterized by three principal features within the brain: Amyloid plaques, anomalous clumps formed from proteins, remnants of neurons, and fragments of other nerve cells. Neurofibrillary tangles (NETs), knotted bundles of fibers, containing clusters of a protein known as tau, are situated within neurons. The deterioration of connections between neurons leads to memory and learning deficits. Alzheimer's disease exhibits distinctive brain alterations (pathology) distinct from those of other causes of dementia, such as Lewy body disease or Cerebrovascular disease. When these coexisting pathologies are identified during a person's lifetime, it is called mixed dementia. A common initial clinical symptom includes difficulty recollecting recent conversations, names, or events, accompanied by apathy and depression. Alzheimer's disease typically advances gradually through three stages: early, middle, and late. The progression of Alzheimer's disease can be categorized into seven stages:

1.       Stage 1: Occurring before the onset of symptoms.

2.       Stage 2: Characterized by mild forgetfulness.

3.       Stage 3: Marked by noticeable memory difficulties.

4.       Stage 4: Involves more than just memory loss.

5.       Stage 5: Results in decreased independence.

6.       Stage 6: Presents severe symptoms.

7.       Stage 7: Features a loss of physical control.

While there is no known cure for Alzheimer's disease, treatments exist to manage its symptoms. These treatments encompass:

·       Cholinesterase inhibitors enhance cell-to-cell communication. Commonly prescribed cholinesterase inhibitors encompass Donepezil (Aricept), Galantamine (Razadyne), and Rivastigmine (Exelon).

·       Memantine, an NMDA antagonist, is prescribed for moderate to severe Alzheimer's.

·       Lecanemab (Leqembi), an FDA-approved medication as of 2023 for individuals with mild Alzheimer's disease and cognitive impairment.

The likelihood of developing Alzheimer's dementia rises with age, affecting 5.3% of those aged 65-74, 13.8% of those aged 75-84, and 34.6% of those aged 85 and above. While Alzheimer's can occur in individuals younger than 65, it is much less common, and its prevalence in this age group remains uncertain.

 

Thelansis’s “Alzheimer’s Disease (AD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Alzheimer’s Disease (AD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Alzheimer’s Disease (AD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Alzheimer’s Disease (AD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Alzheimer’s Disease (AD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Alzheimer’s Disease (AD), Alzheimer’s Disease (AD) market outlook, Alzheimer’s Disease (AD) competitive landscape, Alzheimer’s Disease (AD) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more